- Home
- GLUE vs ASM Comparison
GLUE vs ASM Comparison
Compare GLUE & ASM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | ASM |
|---|---|---|
| Founded | 2019 | 1968 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GLUE | ASM |
|---|---|---|
| Price | $10.79 | $4.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $26.88 | $10.51 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $123,672,000.00 | N/A |
| Revenue This Year | N/A | $58.01 |
| Revenue Next Year | N/A | $43.25 |
| P/E Ratio | $72.42 | ★ $67.93 |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $9.68 | $4.05 |
| 52 Week High | $25.77 | $11.99 |
Technical Indicators
Market Signals| Indicator | GLUE | ASM |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 33.15 |
| Support Level | $9.69 | N/A |
| Resistance Level | $12.00 | $6.52 |
| Average True Range (ATR) | 0.55 | 0.22 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 54.30 | 9.66 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.